Markets:

Overview

News

Currencies

International

Treasuries

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

2.390 +0.080 (+3.46%)

Streaming Delayed Price Updated: 12:40 PM EDT, Jul 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗

May 31, 2026

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

Via The Motley Fool

Topics Initial Public Offering

Century Therapeutics (NASDAQ:IPSC) Reports Narrower Loss, Extended Cash Runway to 2029 ↗

March 12, 2026

Via Chartmill

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

4 Analysts Have This To Say About Century Therapeutics ↗

January 22, 2025

Via Benzinga

5 Analysts Assess Century Therapeutics: What You Need To Know ↗

June 04, 2024

Via Benzinga

Century Therapeutics: Q4 Earnings Insights ↗

March 14, 2024

Via Benzinga

Recap: Century Therapeutics Q3 Earnings ↗

November 09, 2023

Via Benzinga

Century Reports Flat Loss in Fiscal Q2 ↗

August 14, 2025

Via The Motley Fool

Monday's after hours session: top gainers and losers ↗

July 07, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 28, 2025

Via Benzinga

Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday ↗

March 24, 2025

Via Benzinga

Demystifying Century Therapeutics: Insights From 4 Analyst Reviews ↗

March 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 19, 2025

Via Benzinga

Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% ↗

November 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 03, 2024

Via Benzinga

Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 15, 2024

Via Benzinga

IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024 ↗

August 08, 2024

IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing ↗

April 11, 2024

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...

Via Benzinga

IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗

March 14, 2024

IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024 ↗

February 22, 2024

While not on everyone’s radar, these enticing entities just might deliver the goods.

Via InvestorPlace

IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data ↗

January 22, 2024

IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these...

Via Benzinga

Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December ↗

December 19, 2023

Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...

Via Benzinga

Topics ETFs

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential ↗

December 05, 2023

Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler.

Via InvestorPlace

Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach ↗

November 27, 2023

Why Are Gamma-Delta T Cells Important In Fighting Cancer?

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday ↗

August 28, 2023

Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares...

Via Benzinga

These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results ↗

August 10, 2023

Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.